Clinical Trial Detail

NCT ID NCT03787602
Title This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Kartos Therapeutics, Inc.
Indications

Merkel cell carcinoma

Therapies

KRT-232

Age Groups: adult senior

Additional content available in CKB BOOST